The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is lauding the approval of three amyloid imaging agents by the U.S. Food and Drug Administration (FDA).
The FDA on June 23 approved an expanded indication for these agents toward Alzheimer’s and dementia imaging and therapy. These include Florbetapir F-18, Flutemetamol F-18, and Florbetaben F-18 PET.
The agents are already in use to visualize amyloid plaques in patients with cognitive decline in suspected Alzheimer’s disease, but the newly expanded labels modernize their role in disease diagnosis and treatment. These include a quantitative measurement of amyloid plaque and its use for therapy monitoring.
The SNMMI said that quantitative assessment of amyloid scans will allow for more precise measurements and that the agents can also be used to predict cognitive decline in patients.
The SNMMI's full statement can be read here.
